128 related articles for article (PubMed ID: 32206932)
1. Systematic profiling of staralog response to acquired drug resistant kinase gatekeeper mutations in targeted cancer therapy.
Yang Y; Qiu Y; Liu X; Liu Y; Yin Y; Li P
Amino Acids; 2020 Apr; 52(4):511-521. PubMed ID: 32206932
[TBL] [Abstract][Full Text] [Related]
2. Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations.
He Y
Arch Pharm (Weinheim); 2020 Jun; 353(6):e1900320. PubMed ID: 32285482
[TBL] [Abstract][Full Text] [Related]
3. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Meng X; Li Y; Tang H; Mao W; Yang H; Wang X; Ding X; Xie S
Amino Acids; 2016 Feb; 48(2):487-97. PubMed ID: 26439378
[TBL] [Abstract][Full Text] [Related]
4. Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
Song X; Liu X; Ding X
J Mol Recognit; 2017 Apr; 30(4):. PubMed ID: 27891677
[TBL] [Abstract][Full Text] [Related]
5. Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer.
Lu J; Zhou K; Yin X; Xu H; Ma B
Comput Biol Chem; 2019 Feb; 78():290-296. PubMed ID: 30605854
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic relative preference profile of pan-kinase inhibitor drug staurosporine towards the clinically occurring gatekeeper mutations in Protein Tyrosine Kinases.
Ren Z; Li Q; Shen Y; Meng L
Comput Biol Chem; 2021 Oct; 94():107562. PubMed ID: 34428735
[TBL] [Abstract][Full Text] [Related]
7. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
8. Systematic profiling of chemotherapeutic drug response to EGFR gatekeeper mutation in non-small cell lung cancer.
Yao J; Zhao X; Ding X
Comput Biol Chem; 2016 Oct; 64():126-133. PubMed ID: 27341162
[TBL] [Abstract][Full Text] [Related]
9. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Godin-Heymann N; Ulkus L; Brannigan BW; McDermott U; Lamb J; Maheswaran S; Settleman J; Haber DA
Mol Cancer Ther; 2008 Apr; 7(4):874-9. PubMed ID: 18413800
[TBL] [Abstract][Full Text] [Related]
10. Integrated Exploitation of the Structural Diversity Space of Chemotherapy Drugs to Selectively Inhibit HER2 T798M Mutant in Lung Cancer.
Wang YW; Zhang HY; Li JS; Wang XW
Chem Biodivers; 2017 Mar; 14(3):. PubMed ID: 27696725
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
12. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
13. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
14. How a Kinase Inhibitor Withstands Gatekeeper Residue Mutations.
Mondal J; Tiwary P; Berne BJ
J Am Chem Soc; 2016 Apr; 138(13):4608-15. PubMed ID: 26954686
[TBL] [Abstract][Full Text] [Related]
15. Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.
Ma Y; Qi B; Ning M; Zhang L; An Z; Zhao J
Eur Biophys J; 2022 Apr; 51(3):283-295. PubMed ID: 35307752
[TBL] [Abstract][Full Text] [Related]
16. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
17. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
Gallant JN; Sheehan JH; Shaver TM; Bailey M; Lipson D; Chandramohan R; Red Brewer M; York SJ; Kris MG; Pietenpol JA; Ladanyi M; Miller VA; Ali SM; Meiler J; Lovly CM
Cancer Discov; 2015 Nov; 5(11):1155-63. PubMed ID: 26286086
[TBL] [Abstract][Full Text] [Related]
18. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
20.
Nanjo S; Arai S; Wang W; Takeuchi S; Yamada T; Hata A; Katakami N; Okada Y; Yano S
Mol Cancer Ther; 2017 Mar; 16(3):506-515. PubMed ID: 28138027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
